Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008;La prise en charge thérapeutique de l'hypertension artérielle pulmonaire par les antagonistes des récepteurs de l'endothéline en 2008

Revue de Medecine Interne

Volumn 29, Issue 4, 2008, Pages 283-289

  Cacoub, P ^a,b   Amoura, Z ^a   Langleben, D ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Sorbonne Université   (France)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Bosentan; Endothelin; ET 1 receptor antagonists; Pulmonary arterial hypertension; Sitaxentan

Indexed keywords

AMBRISENTAN; ANTICOAGULANT AGENT; ANTIRETROVIRUS AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN DERIVATIVE; SITAXSENTAN;

ANTICOAGULANT THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG ANTAGONISM; DRUG SELECTIVITY; EXERCISE; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; LIVER TOXICITY; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MONOTHERAPY; OXYGEN THERAPY; PATHOGENESIS; PULMONARY HYPERTENSION; SHORT SURVEY; VASODILATATION;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION, PULMONARY; ISOXAZOLES; PHENYLPROPIONATES; PYRIDAZINES; RECEPTORS, ENDOTHELIN; SULFONAMIDES; THIOPHENES;

EID: 41149113972     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2007.12.005     Document Type: Short Survey

References (56)

1. Rich S., Dantzker D.R., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107 (1987) 216-223
2. Badesch D.B., Abman S.H., Simonneau G., Rubin L.J., and McLaughlin V.V. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131 (2007) 1917-1928
3. Koh E.T., Lee P., Gladman D.D., and Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 35 (1996) 989-993
4. Stupi A.M., Steen V.D., Owens G.R., Barnes E.L., Rodnan G.P., and Medsger Jr. T.A. Pulmonary hypertension in the Crest syndrome variant of systemic sclerosis. Arthritis Rheum 29 (1986) 515-524
5. Prakash U.B. Respiratory complications in mixed connective tissue disease. Clin Chest Med 19 (1998) 733-746
6. Humbert M., Nunes H., Sitbon O., Parent F., Herve P., and Simonneau G. Risk factors for pulmonary arterial hypertension. Clin Chest Med 22 (2001) 459-475
7. Rich S., Kaufmann E., and Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327 (1992) 76-81
8. Badesch D.B., Tapson V.F., McGoon M.D., Brundage B.H., Rubin L.J., Wigley F.M., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132 (2000) 425-434
9. Simonneau G., Barst R.J., Galie N., Naeije R., Rich S., Bourge R.C., et al., Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
10. Olschewski H., Simonneau G., Galie N., Higenbottam T., Naeije R., Rubin L.J., et al., Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
11. Galie N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., et al., Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
12. Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., Shennib H., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 (1993) 1732-1739
13. Cacoub P., Dorent R., Nataf P., and Carayon A. Endothelin-1 in pulmonary hypertension. N Engl J Med 329 (1993) 1967-1968
14. Cacoub P., Dorent R., Nataf P., Carayon A., Riquet M., Noe E., et al. Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res 33 (1997) 196-200
15. Cacoub P., Dorent R., Maistre G., Nataf P., Carayon A., Piette C., et al. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol 71 (1993) 448-450
16. Veyssier-Belot C., and Cacoub P. Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension. Cardiovasc Res 44 (1999) 274-282
17. Humbert M., Morrell N.W., Archer S.L., Stenmark K.R., MacLean M.R., Lang I.M., et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43 (2004) 13S-24S
18. Jankov R.P., Kantores C., Belcastro R., Yi M., and Tanswell A.K. Endothelin-1 inhibits apoptosis of pulmonary arterial smooth muscle in the neonatal rat. Pediatr Res 60 (2006) 245-251
19. Stewart D.J., Levy R.D., Cernacek P., and Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?. Ann Intern Med 114 (1991) 464-469
20. Arai H., Hori S., Aramori I., Okhubo H., and Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348 (1990) 730-732
21. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., and Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348 (1990) 732-734
22. Evans A.M., Cobban H.J., and Nixon G.F. ETA receptors are the primary mediators of myofilament calcium sensitization induced by ET-1 in rat pulmonary artery smooth muscle: a tyrosine kinase independent pathway. Br J Pharmacol 127 (1999) 153-160
23. Black S.M., Mata-Greenwood E., Dettman R.W., Ovadia B., Fitzgerald R.K., Rienhartz O., et al. Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased blood flow. Circulation 108 (2003) 1646-1654
24. Shi-Wen X., Chen Y., Denton C.P., Eastwood M., Renzoni E.A., Bou-Gharios G., et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Aktdependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 15 (2004) 2707-2719
25. Davie N., Haleen S.J., Upton P.D., Plak J.M., Yacoub M.H., Morrell N.W., et al. ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 165 (2002) 398-405
26. Bauer M., Wilkens H., Langer F., Schneider S.O., Lausberg H., and Schafer H.J. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 105 (2002) 1034-1036
27. De Nucci G., Thomas R., D'Orleans-Juste P., Antunes E., Walder C., Warner T.D., et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A 85 (1988) 9797-9800
28. Dupuis J., Goresky C.A., and Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 81 (1996) 1510-1515
29. Langleben D., Dupuis J., Langleben I., Hirsch A.M., Baron M., Senecal J.L., et al. Etiology specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest 129 (2006) 689-695
30. Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A., Tapson V.F., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 358 (2001) 1119-1123
31. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
32. Galie N., Hinderliter A.L., Torbicki A., Fourme T., Simmoneau G., Pulido T., et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 1380-1386
33. Sitbon O., Badesch D.B., Channick R.N., Frost A., Robbins I.M., Simmoneau G., et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension. Chest 124 (2003) 247-254
34. McLaughlin V.V., Sitbon O., Badesch D.B., Barst R.J., Black C., Galie N., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 (2005) 244-249
35. Sitbon O., McLaughlin V.V., Badesch D.B., Barst R.J., Black C., Galié N., et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 60 (2005) 1025-1030
36. Barst R.J., Ivy D., Dingemanse J., Widlitz A., Schmitt K., Doran A., et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 73 (2003) 372-382
37. Sitbon O., Gressin V., Speich R., MacDonald P.S., Opravil M., Cooper D.A., et al. Bosentan for the treatment of human immunodeficiency virus associated pulmonary arterial hypertension. Am J Respir Crit Care Med 170 (2004) 1212-1217
38. Galie N., Beghetti M., Gatzoulis M.A., Granton J., Berger R.M., Lauer A., et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo controlled study. Circulation 114 (2006) 48-54
39. Barst R.J., Rich S., Widlitz A., Hom E.M., McLaughlin V., and McFarlin J. Clinical efficacy of sitaxentan, an oral endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension. Chest 121 (2002) 1860-1868
40. Barst R.J., Langleben D., Frost A., Horn E.M., Oudiz R., Shapiro S., et al. Sitaxentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169 (2004) 441-447
41. Barst R.J., McGoon M., McLaughlin V., Tapson V., Rich S., Rubin L., et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 2119-2125
42. Oudiz R.J., Barst R.J., Hansen J.E., Sun X.G., Garofano R., Wu X., et al. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. Am J Cardiol 97 (2006) 123-126
43. Langleben D., Hirsch A.M., Shalit E., Lesenko L., and Barst R.J. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxentan, in patients with pulmonary arterial hypertension. Chest 126 (2004) 1377-1381
44. Barst R.J., Langleben D., Badesch D., Frost A., Lawrence E.C., Shapiro S., et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxentan. J Am Coll Cardiol 47 (2006) 2049-2056
45. Pulido T., Kurzyna M., and Souza R. Sitaxentan 100 mg proves more effective than sitaxentan 50 mg in patients with pulmonary arterial hypertension. Proc Am Thorac Soc 3 (2006) A417
46. Benza R., Frost A., and Girgis R. Chronic treatment of pulmonary arterial hypertension with sitaxentan and bosentan. Proc Am Thorac Soc 3 (2006) A729
47. Benza R., Mehta S., and Keogh A. Sitaxentan treatment for patients with pulmonary arterial hypertension failing bosentan treatment. Proc Am Thorac Soc 2 (2005) A201
48. Galie N., Badesch D.B., Oudiz R., Simmoneau G., McGoon M.D., Keogh A.M., et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46 (2005) 529-535
49. Olschewski H., Galie N., and Ghofrani H.A. Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension. Proc Am Thorac Soc 3 (2006) A728
50. Provencher S., Sitbon O., Humbert M., Cabrol S., Jais X., and Simmoneau G. Long term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 27 (2006) 589-595
51. Kim N.H., Channick R.N., and Rubin L.J. Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension. Chest 124 (2003) 1612-1615
52. Ivy D.D., Doran A., Claussen L., Bingaman D., and Yetman A. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol 93 (2004) 943-946
53. Suleman N., and Frost A.E. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension. Chest 126 (2004) 808-815
54. Hoeper M.M., Taha N., Bekjarova A., Gatzke R., and Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 22 (2003) 330-334
55. Humbert M., Barst R.J., Robbins I.M., Channick R.N., Galie N., Boonstra A., et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24 (2004) 353-359
56. McLaughlin V.V., Oudiz R., Frost A., Tapson V.F., Murali S., Channick R.N., et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174 (2006) 1257-1263